

National Board of Examinations

Question Paper Name :	DNB Radiation Oncology Paper3
Subject Name :	DNB Radiation Oncology Paper3
Creation Date :	2023-10-15 15:58:45
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DNB Radiation Oncology Paper3

Group Number :	1
Group Id :	3271872543
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DNB Radiation Oncology Paper3

Section Id :	3271872546
Section Number :	1
Section type :	Offline

Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872550
Question Shuffling Allowed :	No
Is Section Default? :	null

Question Number : 1 Question Id : 32718725803 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Discuss the role of radiotherapy in operable carcinoma rectum with reference to the results of major phase III trials. [5]
- b) Discuss the incorporation of chemotherapy in the treatment algorithm. [5]

Question Number : 2 Question Id : 32718725804 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Classify CNS tumors. [5]
- b) Describe the management of medulloblastoma. [5]

Question Number : 3 Question Id : 32718725805 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Supportive therapy in metastatic tumors. [5]
- b) Solitary 4 cm lesion in segment IV of liver: Management options. [5]

Question Number : 4 Question Id : 32718725806 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Enumerate the role of radiotherapy in the management of non-malignant conditions. [10]

Question Number : 5 Question Id : 32718725807 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) What are Gliadel wafers and how they are advantageous? [5]
- b) Radiotherapy in cerebellar sarcoma. [5]

Question Number : 6 Question Id : 32718725808 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Rituximab. [5]
- b) Cetuximab. [5]

Question Number : 7 Question Id : 32718725809 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Correct Marks : 10

- a) Extracorporeal irradiation. [5]
- b) Role of EBRT in osteogenic sarcoma. [5]

Question Number : 8 Question Id : 32718725810 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Write a note on prevention and management of radiation sequelae in a patient of carcinoma breast. How will you guide the patient? [10]

Question Number : 9 Question Id : 32718725811 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Brachytherapy in carcinoma oesophagus. [5]
- b) Management of basal cell carcinoma by radiotherapy. [5]

Question Number : 10 Question Id : 32718725812 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Describe the role of molecular and genetic markers in Oncology with special reference to lung and colon. [10]